Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-04-29
2008-04-29
Pak, John (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S001000, C514S458000, C514S879000
Reexamination Certificate
active
07365049
ABSTRACT:
The use of Afamin, in particular in combination with vitamin E is described for producing a preparation for the treatment of oxidative stress.
REFERENCES:
patent: WO 95/27059 (1995-10-01), None
patent: WO 01/01148 (2001-01-01), None
Grundman M. Vitamin E and Alzheimer disease: the basis for additional clinical trials Am J Clin Nutr 2000, 71(S), 630S-636S.
Christen, “Oxidative stress and Alzheimer disease.,”Am. J. Clin. Nutr., 71(2):621s-629s, 2000.
Ebadi et al., “Oxidative stress and antioxidant therapy in Parkinson's disease.,”Prog. Neurobiol., 48(1):1-19, 1996.
Ghadge et al., “Mutant superoxide dismutase-1-linked familial amyotrophic lateral sclerosis: molecular mechanisms of neuronal death and protection,”J. Neurosci., 17(22):8756-8766, 1997.
Jerkovic et al., “Afamin and vitamin E in follicular fluid of patients undergoing IVF,”Human Reproduction, 14(abstr. Book 1):203-204, 1999.
Jovanovic et al., “Biomarkers of oxidative stress are significantly elevated in down syndrome,”Free Radic. Res., 9:1044-1048, 1998.
Lichenstein et al., “Afamin is a new member of the albumin, alpha-fetoprotein, and vitamin D-binding protein gene family,”J. Biol. Chem., 269(27):18149-18154, 1994.
Mazel et al., “Doxorubicin-peptide conjugates overcome multidrug resistance,”Anticancer Drugs, 12(2):107-116, 2001.
Peyser et al., “Trial of d-alpha-tocopherol in Huntington's disease,”Am. J. Psychiatry, 152:1771-1775, 1995.
Post et al., “Induction of NF-kappaB activity during haloperidol-induced oxidative toxicity in clonal hippocampal cells: suppression of NF-kappaB and neuroprotection by antioxidants.,”J. Neurosci., 18(20):8236-8246, 1998.
Rouselle et al., “Enhanced delivery of doxorubicin into the brain via a peptide-vector-mediated strategy: saturation kinetics and specificity,”J. Pharmacol. Exp. Ther., 296(1):124-131, 2001.
Rousselle et al., “New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy,”Mol. Pharmacol., 57(4):679-686, 2000.
Temsamani et al., “Brain drug delivery technologies: novel approaches for transporting therapeutics,”Phar. Sci. Technol. Today, 3(5):155-162, 2000.
Teunissen et al., “Cognitive performance in combination with serum markers in an aging population: a 6 year follow-up study as part of the Maastricht Aging Study,”Society for Neuroscince Abstracts, 26(1-2):abstract No. 575.3, 2000.
Chwatal, “Bilirubin binding stuides by means of enzymatic oxidation,”Molecular Analysis of a Human Plasma Protein of the Albumin Gene Family, 1996 [translated].
Groenendijk et al., “apoAI-CIII-AIV gene cluster,”Atherosclerosis, 157:1-11, 2001.
Jerkovic et al., “Afamin Is a Novel Human Vitamin E-Binding Glycoprotein Characterization and In Vitro Expression,”J of Proteome Research, 4:889-899, 2005.
Karathanasis, “Apolipoprotein multigene family: Tandem organization of humans apolipoprotein AI, CIII, and AIV genes,”Proc Nat'l Acad Sci USA, 82:6374-6378, 1985.
Lichenstein et al., “Afamin Is a New Member of the Albumin, alpha-Fetoprotein, and Vitamin D-binding Protein Gene Family,”J Biol. Chem., 269:18149-18154, 1994.
Mizejewski, “Alpha-fetoprotein Structure and Function: Relevance to Isoforms, Epitopes, and Conformational Variants,”Exp Biol Med, 266:377-408, 2001.
Petersen et al., “Vitamin E and Donepezil for the treatment of mild cognitive impairment,”New England J Medicine, 352:2379-2388, 2005.
van Dijk et al., “The role and mode of action of apolipoproteins CIII and AV: synergistic actors in triglyceride metabolism,”Current Opinon Lipdol, 15:236-246, 2004.
Voegele et al., “Characterization of the Vitamin E-Binding Properties of Human Plasma Afamin,”Biochemistry, 41:14532-14538, 2002.
Becker-Andre Michael
Dieplinger Hans
Jerkovic Lidija
Teunissen Charlotte
Arnold Ernst V
Fulbright & Jaworski LLP
Pak John
Vitateg Biotechnology GmbH
LandOfFree
Afamin-containing compositions and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Afamin-containing compositions and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Afamin-containing compositions and methods of use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2793218